Preview

Current Pediatrics

Advanced search

RESULTS OF MASS SCREENING OF NEWBORNS WITH CYSTIC FIBROSIS IN MOSCOW

Abstract

Neonatal screening of cystic fibrosis is able to provide early presymptomatic diagnosis of the disease in newborns. The objective of this study was to evaluate an effectiveness of neonatal cystic fibrosis screening in Moscow. Authors studied molecular-genetical samples of DNA in 1,260 newborns with hypertripsinogenemia (the level of immunoreactive tripsin in first test — IRT I was > 70 ng/ml) for the presence of most frequent mutations of gene CFTR. All children were born in Moscow in 2008. They formed risk group because of results of IRT I test. Mutations were detected in 53 persons (47 heterozygotes and 6 homozygotes). The rate of false-negative results was 0.16 %; the result was similar to European data.
Key words: newborns, neonatal screening, cystic fibrosis, hypertripsinogenemia, CFTR gene, mutations.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(6):26-30)

About the Authors

Z.A. Kusova
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation



N.V. Petrova
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation


T.A. Vasil'eva
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation



N.Yu. Kashirskaya
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation


R.A. Zinchenko
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation




N.I. Kapranov
Medical Genetics Scientific Center, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Brice P., Jarrett J., Mugford M. Genetic screening for cystic fibrosis: An overview of the science and the economics. J. Cystic Fibrosis. 2007; 6: 255–261.

2. Castellani C., Southern K.W., Brownlee K. et al. European best practice guidelines for cystic fibrosis neonatal screening. J. Cystic Fibrosis. 2009; 8: 153–173.

3. Kharrazi M., Kharrazi L.D. Delayed diagnosis of cystic fibrosis and the family perspective. J. Pediatr. 2005; 147: 21–25.

4. Муковисцидоз. Современные достижения и актуальные проблемы. Методические рекомендации. Издание третье (первое 2001) переработанное и дополненное. Под ред. Капранова Н.И., Каширской Н.Ю. М.: 4ТЕ Арт. 2008. 124 с.

5. Cheillan D., Vercherat M., Chevalier–Porst F. et al. False-positive results in neonatal screening for cystic fibrosis based on a three stage protocol (IRT/DNA/IRT): should we adjust IRT cut-off to ethnic origin? J. Inherit Metab. Disease. 2005; 28: 813–818.

6. Rock M.J., Mischler E.H., Farrell P.M. et al. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990; 85 (6): 1001–1007.

7. Comeau A.M., Parad R.B., Dorkin H.L. et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a CF newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004; 113(6): 1573–1581.

8. Crossley J.R., Elliott R.B., Smith P.A. Dried blood spot screening for cystic fibrosis in the newborn. Lancet. 1979; 1(8114): 472–474.

9. Giusti R. New York State Cystic Fibrosis Newborn Screening Consortium. Elevated IRT levels in African-American infants: implications for newborn screening in an ethnically diverse population. Pediatr. Pulmonol. 2008; 43: 638–641.

10. Heeley A.F., Fagan D.G. Trisomy 18, cystic fibrosis, and blood immunoreactive trypsin. Lancet. 1984; 1: 169–170.

11. Priest F.J., Nevin N.C. False positive results with immunoreactive trypsinogen screening for cystic fibrosis owing to trisomy 13. J. Med. Genet. 1991; 28: 575–576.

12. Sarles J., Barthellemy S., Férec C. et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch. Dis. Child Fetal. Neonatal Ed. 1999; 80 (2): 118–122.

13. Iovanna J.L., Férec C., Sarles J., Dagorn J.C. The pancreatitis-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. Acad. Sci. 1994; 317 (6): 561–564.

14. Толстова В.Д., Каширская Н.Ю., Капранов Н.И. Массовый скрининг новорожденных на муковисцидоз в России. Фарматека. 2008; 1: 1–5.

15. Животовский Л.А. Популяционная биометрия. М.: Наука. 1991. 271 с.

16. Петрова Н.В. Определение относительных частот некоторых мутаций гена CFTR и анализ гаплотипов сцепленных с ними ДНК–маркерных локусов в Популяции России. Автореф. дис. … канд. биол. наук. М. 1996. 24 с.

17. Петрова Н.В., Тимковская Е.Е., Зинченко Р.А., Гинтер Е.К. Анализ частоты некоторых мутаций в гене CFTR в разных популяциях России. Медицинская генетика. 2006; 2: 32–39.

18. Southern K.W., Munck A., Pollit R. et al. A survey of newborn screening for cystic fibrosis in Eur. J. Cystic Fibrosis. 2007; 6: 57–65.


Review

For citations:


Kusova Z., Petrova N., Vasil'eva T., Kashirskaya N., Zinchenko R., Kapranov N. RESULTS OF MASS SCREENING OF NEWBORNS WITH CYSTIC FIBROSIS IN MOSCOW. Current Pediatrics. 2010;9(6):26-30.

Views: 994


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)